{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:56Z","timestamp":1747181216889,"version":"3.40.5"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,9]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>The efficacy of adalimumab versus methotrexate for psoriasis remained controversial. We conducted this systematic review and meta-analysis to explore the influence of adalimumab versus methotrexate on treatment efficacy for psoriasis patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We have searched PubMed, EMbase, Web of Science, EBSCO, and Cochrane Library databases through August 2023 for randomized controlled trials (RCTs) assessing the efficacy of adalimumab versus methotrexate for psoriasis. This meta-analysis was performed using the random-effect or fixed-effect model based on the heterogeneity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Four RCTs and 733 patients with psoriasis were included in this meta-analysis. Overall, compared with methotrexate treatment, adalimumab treatment was associated with improved Psoriasis Area and Severity Index 75 (PASI 75, odd ratio [OR]\u2005=\u20054.50; 95% confidence interval [CI]\u2005=\u20052.81\u20137.22; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001), physician global assessment (PGA) 0\/1 response (OR\u2005=\u20054.86; 95% CI\u2005=\u20053.02\u20137.82; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001), PASI 100 (OR\u2005=\u20053.01; 95% CI\u2005=\u20051.33\u20136.80; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.008) and decreased Dermatology Life Quality Index (DLQI, standard mean difference [SMD]\u2005=\u2005\u22120.60; 95% CI\u2005=\u2005\u22120.84 to \u22120.36; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001), but exhibited no impact on PASI 90 (OR\u2005=\u20053.30; 95% CI\u2005=\u20050.77\u201314.20; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.11), adverse events (OR\u2005=\u20051.23; 95% CI\u2005=\u20050.26\u20135.87; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.79) or serious adverse events (OR\u2005=\u20052.59; 95% CI\u2005=\u20050.49\u201313.79; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.26).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Adalimumab was superior to methotrexate for the treatment of psoriasis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000037216","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T18:39:04Z","timestamp":1723228744000},"page":"e37216","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of adalimumab with methotrexate for psoriasis: A meta-analysis of randomized controlled studies"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0293-4814","authenticated-orcid":false,"given":"Xiaolin","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Skin Burn Wound Repair, Chongqing Kaizhou District People\u2019s Hospital, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, Chongqing Kaizhou District People\u2019s Hospital, Chongqing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence.","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial.","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjd.21718","article-title":"Alcohol consumption and smoking in relation to psoriasis: a Mendelian randomization study.","volume":"187","author":"Wei","year":"2022","journal-title":"Br J Dermatol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.det.2023.02.002","article-title":"Diagnosing psoriasis in skin of color patients.","volume":"41","author":"Khanna","year":"2023","journal-title":"Dermatol Clin"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/1346-8138.16737","article-title":"Survival rates of systemic interventions for psoriasis in the Western Japan psoriasis registry: a multicenter retrospective study.","volume":"50","author":"Yanase","year":"2023","journal-title":"J Dermatol"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2009.07.029","article-title":"Incidence of psoriasis in children: a population-based study.","volume":"62","author":"Tollefson","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"adv00020","DOI":"10.2340\/00015555-3375","article-title":"Psoriasis and mental health workshop report: exploring the links between psychosocial factors, psoriasis, neuroinflammation and cardiovascular disease risk.","volume":"100","author":"Kleyn","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"e2021055","DOI":"10.5826\/dpc.1103a55","article-title":"Management of a chronic skin disease in primary care: an analysis of early-career general practitioners\u2019 consultations involving psoriasis.","volume":"11","author":"Nawaz","year":"2021","journal-title":"Dermatol Pract Concept"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2147\/TCRM.S4908","article-title":"Pediatric psoriasis: an update.","volume":"5","author":"Silverberg","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"R11-20250503","first-page":"1","article-title":"Systemic and light therapies for the management of childhood psoriasis: part II.","volume":"13","author":"Cordoro","year":"2008","journal-title":"Skin Therapy Lett"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaad.2009.08.026","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.","volume":"62","author":"Menter","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review.","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.","volume":"84","author":"Elmets","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/bjd.18029","article-title":"Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study.","volume":"181","author":"Tha\u00e7i","year":"2019","journal-title":"Br J Dermatol"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jamadermatol.2015.0452","article-title":"CCL20 and IL22 messenger RNA expression after adalimumab vs methotrexate treatment of psoriasis: a randomized clinical trial.","volume":"151","author":"Goldminz","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses.","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Ann Intern Med"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2007.08236.x","article-title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.","volume":"158","author":"Revicki","year":"2008","journal-title":"Br J Dermatol"},{"key":"R24-20250503","first-page":"33","article-title":"Management of scalp psoriasis: current perspectives.","volume":"6","author":"Blakely","year":"2016","journal-title":"Psoriasis (Auckl)"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/09546634.2012.681017","article-title":"Long-term management of scalp psoriasis: perspectives from the International Psoriasis Council.","volume":"24","author":"Kragballe","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"R26-20250503","first-page":"CD009687","article-title":"Nast, Topical treatments for scalp psoriasis.","volume":"2","author":"Schlager","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis.","volume":"358","author":"Paller","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:37:37Z","timestamp":1746319057000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":26,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037216","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,8,9]]}}}